APA (7th ed.) Citation
(2026). PEGylated thymosin β4 is a thiol‐site‐specific prodrug treating myocardial infarction in vivo. Bioengineering & Translational Medicine.
Chicago Style (17th ed.) Citation
"PEGylated Thymosin β4 Is a Thiol‐site‐specific Prodrug Treating Myocardial Infarction in Vivo." Bioengineering & Translational Medicine 2026.
MLA (9th ed.) Citation
"PEGylated Thymosin β4 Is a Thiol‐site‐specific Prodrug Treating Myocardial Infarction in Vivo." Bioengineering & Translational Medicine, 2026.
Warning: These citations may not always be 100% accurate.